3-(氯磺酰基)-4-甲基苯甲酸 | 2548-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(氯磺酰基)-4-甲基苯甲酸
• 中文别名: 3-磺酰氯-4-甲基苯甲酸；3-氯磺酰基-4-甲基苯甲酸
• 英文名称: 3-(chlorosulfonyl)-4-methylbenzoic acid
• 英文别名: 3-Chlorsulfonyl-4-methyl-benzoesaeure；3-Chlorosulfonyl-4-methylbenzoic acid
• CAS: 2548-29-0
• 化学式: C₈H₇ClO₄S
• mdl: MFCD00625710
• 分子量: 234.66
• InChiKey: XVAASXODNQTGCP-UHFFFAOYSA-N

物化性质

• 熔点：
  173 °C(Solv: chloroform (67-66-3))
• 沸点：
  420.0±38.0 °C(Predicted)
• 密度：
  1.514±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P280,P303+P361+P353,P301+P330+P331,P304+P340+P310,P305+P351+P338+P310
• 危险品运输编号：
  3261
• 危险性描述：
  H314
• 储存条件：
  室温下，应保存在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Chlorosulfonyl-4-methyl-benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chlorosulfonyl-4-methyl-benzoic acid
CAS number: 2548-29-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7ClO4S
Molecular weight: 234.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(氯磺酰基)-4-甲基苯甲酸 在 氯化亚砜 、 sodium hydride 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 6.66h， 生成
  参考文献：
  名称：

  基于邻氨基苯甲酸的复制蛋白A抑制剂的鉴定和优化。

  摘要：

  复制蛋白A（RPA）是必不可少的单链DNA（ssDNA）结合蛋白，可通过其70N结构域介导的蛋白-蛋白相互作用（PPI）引发DNA损伤反应途径。可以特异性破坏这些相互作用的化学探针的鉴定和使用对于验证RPA作为癌症靶标非常重要。进行了高通量筛选（HTS）以识别新的化学实体，并鉴定了90种命中化合物。从这些最初的命中，通过使用结构指导的迭代药物化学方法优化了基于邻氨基苯甲酸的系列，以产生细胞渗透性化合物，其以812 nm的亲和力与RPA70N结合。该化合物2-（3-（N-（N-（3,4-二氯苯基）氨磺酰基）-4-甲基苯甲酰胺基）苯甲酸（20 c），能够抑制由该结构域介导的PPI。

  DOI：

  10.1002/cmdc.201500479
• 作为产物：
  描述：

  对甲基苯甲酸甲酯 在 氯磺酸 作用下， 反应 5.0h， 以35%的产率得到3-(氯磺酰基)-4-甲基苯甲酸
  参考文献：
  名称：

  WO2007/124546

  摘要：

  公开号：

文献信息

• Design and synthesis of benzenesulfonamide‐linked imidazo[2,1‐ <i>b</i> ][1,3,4]thiadiazole derivatives as carbonic anhydrase I and II inhibitors
  作者：Baijayantimala Swain、Kamtam Aashritha、Priti Singh、Andrea Angeli、Abhay Kothari、Dilep K. Sigalapalli、Venkata M. Yaddanapudi、Claudiu T. Supuran、Mohammed Arifuddin

  DOI：10.1002/ardp.202100028

  日期：2021.7

  A novel series of imidazothiadiazole-linked benzenesulfonamide derivatives (5a–t) was synthesized and subjected for screening against the four physiologically and pharmacologically relevant human carbonic anhydrase (hCA) isoforms: hCA I, II, VA, and IX. The compounds selectively inhibited hCA I and II over hCA VA and IX. Furthermore, among the two cytosolic isoforms, hCA II was more effectively inhibited

  合成了一系列新型咪唑并噻二唑连接的苯磺酰胺衍生物 ( 5a – t )，并针对四种生理学和药理学相关的人碳酸酐酶 (hCA) 亚型：hCA I、II、VA 和 IX 进行筛选。与 hCA VA 和 IX 相比，这些化合物选择性抑制 hCA I 和 II。此外，在两种胞质亚型中，与 hCA I 相比，hCA II 受到更有效的抑制。对 hCA II 最活性的化合物是5o （ K i = 0.246 µM）和5p （ K i = 0.376 µM），而化合物5f显示出良好的抑制作用针对 hCA I 和 II， K i分别为 0.493 和 0.4 µM。这类尚未充分研究的磺胺类药物可用于设计针对药物化学感兴趣的酶的异构体选择性 CA 抑制剂。
• [EN] ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉASES MATRICIELLES À BASE D'ARYLSULFONAMIDES
  申请人：NOVARTIS AG

  公开号：WO2009118292A1

  公开（公告）日：2009-10-01

  The present invention provides a compound of formula (I):said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP- 13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP- 13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种化合物，其化学式为(I)：所述化合物是MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13异常活性特征的疾病或疾病。因此，化合物(I)的化合物可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12、和/或MMP-13介导的疾病或疾病。最后，本发明还提供了一种药物组合物。
• [EN] PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY<br/>[FR] PYRAZOLO[1,5-A]PYRIDINES ET LEUR UTILISATION EN CANCÉROTHÉRAPIE
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2009008748A1

  公开（公告）日：2009-01-15

  Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  Pyrazolo[1,5-a]吡啶类化合物被描述，包括它们的制备方法，以及它们作为抗癌治疗药物或药剂的用途，无论是单独使用还是与放疗和/或其他抗癌药物联合使用。
• 3-Functionalised benzenesulphonamide based 1,3,4-oxadiazoles as selective carbonic anhydrase XIII inhibitors: Design, synthesis and biological evaluation
  作者：Baijayantimala Swain、Abhay、Priti Singh、Andrea Angeli、Kamtam Aashritha、Narayana Nagesh、Claudiu T. Supuran、Mohammed Arifuddin

  DOI：10.1016/j.bmcl.2021.127856

  日期：2021.4

  A new series of benzenesulphonamide linked-1,3,4-oxadiazole hybrids (6a–s) has been synthesized and tested for their carbonic anhydrase inhibition against human (h) carbonic anhydrase (CA) isoforms hCA I, II, IX, and XIII. Fluorescence properties of some of the synthesized molecules were studied. Most of the molecules exhibited significant inhibitory power, comparable or better than the standard drug

  合成了一系列新的苯磺酰胺连接的 1,3,4-恶二唑杂化物 ( 6a – s )，并测试了其对人 (h) 碳酸酐酶 (CA) 亚型 hCA I、II、IX 和 XIII 的碳酸酐酶抑制作用。研究了一些合成分子的荧光特性。大多数分子对 hCA XIII 表现出显着的抑制能力，与标准药物乙酰唑胺 (AAZ) 相当或更好。在 19 个测试分子中，化合物6e (75.8 nM) 的抗 hCA I 效力是 AAZ (250.0 nM) 的 3 倍，而化合物6e (15.4 nM)、 6g (16.2 nM)、 6h (16.4 nM) 和6i (17.0 nM) nM) 被发现比 AAZ (17.0 nM) 对抗异构体 hCA XIII 更有效。预计这些化合物可作为开发具有改进效力的选择性 hCA XIII 亚型抑制剂的潜在先导化合物。
• Synthesis, Characterization and Antimicrobial Activity of Bifunctional Sulfonamide-Amide Derivatives
  作者：Babul Reddy A. Abbavaram、Hymavathi R.V. Reddyvari

  DOI：10.5012/jkcs.2013.57.6.731

  日期：2013.12.20

  A convenient synthesis of bifunctional sulfonamide-amide derivatives was reported. Amide coupling of 4-methyl benzoic acid 1 followed by reaction with chlorosulfonic acid produce ethyl-4-(3-(chlorosulfonyl)-4-methylbenzoyl)piperazine-1-carboxylate 4. The resulted compound on further treatment with various anilines produces the title sulfonamide-amide derivatives 5a-n. The configurations of these compounds were established by elemental analysis, IR, $^1H$ NMR, mass spectra, and by their preparation from the corresponding 4-methyl benzoic acid 1 and chlorosulfonic acid. All these new compounds demonstrate significant in vitro antibacterial and antifungal activities against all bacterial and fungal strains.

  报道了一种方便的双功能磺胺酰胺衍生物的合成方法。首先通过4-甲基苯甲酸1的酰胺偶联反应，再与氯磺酸反应，生成乙基-4-（3-（氯磺酰基）-4-甲基苯甲酰基）哌嗪-1-羧酸酯4。所得化合物进一步与各种苯胺反应，生成目标磺胺酰胺衍生物5a-n。这些化合物的结构通过元素分析、红外光谱、$^1H$核磁共振、质谱以及从相应的4-甲基苯甲酸1和氯磺酸制备得到确认。所有这些新化合物均显示出显著的体外抗菌和抗真菌活性，对所有细菌和真菌株有效。